Medications

A third oral GLP-1 is in the pipeline. Here's what the Phase 2b data shows.

Phase 2b data shows aleniglipron achieved up to 11.3% placebo-adjusted weight loss at 36 weeks. Here's what that means for the oral GLP-1 pipeline.

4 min read · Updated 2026-06-13

Peptide GPS publishes educational information, not medical advice. We don't sell, prescribe, or recommend specific medications, dosages, or providers. Always discuss any therapy with a licensed clinician.

Key takeaways

Phase 2b data published in Nature Medicine found aleniglipron achieved up to 11.3% placebo-adjusted weight loss at 36 weeks (120 mg dose)
This is Phase 2b data — smaller and shorter than Phase 3 trials required for approval
Aleniglipron is investigational. Not FDA-approved. No prescribing pathway.
GI side effects were mild to moderate and decreased over time; treatment-related discontinuations were 10.4%
No drug-induced liver injury was observed
The weight-loss curve had not reached a plateau at trial's end

What aleniglipron is

Aleniglipron is a once-daily oral small molecule developed by Structure Therapeutics. Like orforglipron, it is a non- . It does not have the food/water timing restrictions of earlier oral peptide formulations and is taken once daily regardless of meals.

What the ACCESS Phase 2b trial found

The ACCESS Phase 2b trial (NCT06693843) enrolled 230 adults with (mean 39.5, 54% female) and tested aleniglipron at 45 mg, 90 mg, or 120 mg daily, or , over 36 weeks.

Placebo-adjusted weight loss at 36 weeks:

45 mg: -8.2%
90 mg: -9.8%
120 mg: -11.3%

Total weight loss at the highest dose was approximately 14.7%. The weight-loss curve showed no apparent plateau at 36 weeks. GI adverse events were mild to moderate and decreased in frequency over time. Treatment-related discontinuations: 10.4% across aleniglipron arms. No drug-induced liver injury observed.

What placebo-adjusted weight loss means

The figures reported (8.2–11.3%) represent the difference between aleniglipron arms and placebo arm. Total weight loss in treated groups is higher. This distinction matters when comparing across trials.

How these results compare to other oral GLP-1 options

Orforglipron (Foundayo) achieved approximately 12.4% placebo-adjusted weight loss at 72 weeks in Phase 2b. Aleniglipron's 11.3% at 36 weeks with an ongoing trajectory is broadly comparable at a shorter timepoint — but a direct comparison requires a head-to-head trial.

Oral semaglutide for weight management is separately approved, but requires strict fasting before and after dosing — a restriction aleniglipron does not carry.

What the data does not tell us yet

outcomes: Phase 2b establishes proof of concept. Phase 3 — typically thousands of participants over 52-72+ weeks — can differ meaningfully.

Cardiovascular outcomes: No CVOT data for aleniglipron exists.

Approval timeline: Structure Therapeutics had not announced a Phase 3 timeline or NDA filing date as of June 2026.

Questions to ask your clinician

Is an oral GLP-1 appropriate for my clinical situation compared to an injectable?
How do Foundayo and oral semaglutide differ in dosing restrictions and evidence profile?
If aleniglipron enters Phase 3, would I be a candidate for enrollment?

Two oral GLP-1s are FDA-approved. Your prescriber can walk you through the evidence. Aleniglipron is still in development — the ACCESS Phase 2b data is the latest, not the last, word.

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

Nature Medicine, Rosenstock et al., June 2026: nature.com
ClinicalTrials.gov NCT06693843: clinicaltrials.gov
Structure Therapeutics press release, June 7, 2026: biospace.com

Get the weekly brief

One plain-English email per week on GLP-1s, peptides, and the regulation around them.